| Bioactivity | LXJ-02 is a potent inhibitor of EDPs/EBP peptide–protein interaction, with the KD of 117 μM for EDPs. LXJ-02 activates the macrophage-MMP-12 axis to increase MMP-12 expression and degrade ECM components like elastin[1]. |
| CAS | 2672508-37-9 |
| Sequence | {PEG2-PEG2}-{gamma-Glu}-{CO(CH2)18CO2H)}-Val-{Iva}-Gly-Ser-Pro-Ser-Ala-Gln-Glu-Glu-Ala-Ser-Pro-Ala-NH2 |
| Shortening | {PEG2-PEG2}-{gamma-Glu}-{CO(CH2)18CO2H)}-V-{Iva}-GSPSAQEEASPA-NH2 |
| Formula | C94H159N19O34 |
| Molar Mass | 2099.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yixiang Wang, et al. Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment. J Med Chem. 2024 Apr 25;67(8):6624-6637. |
LXJ-02
CAS: 2672508-37-9 F: C94H159N19O34 W: 2099.37
LXJ-02 is a potent inhibitor of EDPs/EBP peptide–protein interaction, with the KD of 117 μM for EDPs. LXJ-02 activates
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.